ALK INHIBITOR PLUS VINBLASTINE FOR REFRACTORY/RELAPSED PEDIATRIC ALK+ ANAPLASTIC LARGE CELL LYMPHOMA: A PROSPECTIVE, ONE-ARM, OPEN-LABEL REAL-WORLD STUDY. (October 2022)